Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19

W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020 - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …

[HTML][HTML] Emerging topical and systemic JAK inhibitors in dermatology

F Solimani, K Meier, K Ghoreschi - Frontiers in immunology, 2019 - frontiersin.org
Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …

[HTML][HTML] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

L Hoisnard, B Lebrun-Vignes, S Maury, M Mahevas… - Scientific Reports, 2022 - nature.com
Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic
haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess …

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

M Marchetti, AM Vannucchi, M Griesshammer… - The Lancet …, 2022 - thelancet.com
Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …

[HTML][HTML] Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib

EM Elli, C Baratè, F Mendicino, F Palandri… - Frontiers in …, 2019 - frontiersin.org
The JAK-STAT signaling pathway plays a central role in signal transduction in hematopoietic
cells, as well as in cells of the immune system. The occurrence in most patients affected by …

[HTML][HTML] Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation

F Perner, C Perner, T Ernst, FH Heidel - Cells, 2019 - mdpi.com
Clonal alterations in hematopoietic cells occur during aging and are often associated with
the establishment of a subclinical inflammatory environment. Several age-related conditions …

[HTML][HTML] Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on …

G Maschmeyer, J De Greef, SC Mellinghoff, A Nosari… - Leukemia, 2019 - nature.com
A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Kinases as potential therapeutic targets for anti-coronaviral therapy

T Pillaiyar, S Laufer - Journal of Medicinal Chemistry, 2021 - ACS Publications
The global coronavirus disease-19 (COVID-19) has affected more than 140 million and
killed more than 3 million people worldwide as of April 20, 2021. The novel human severe …

Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

F Palandri, M Breccia, M Bonifacio, N Polverelli… - Cancer, 2020 - Wiley Online Library
Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis
reportedly has been poor. The authors investigated whether disease characteristics before …

[HTML][HTML] Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape

HT Greinix, F Ayuk, R Zeiser - Leukemia, 2022 - nature.com
Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor
prognosis and for decades no approved drug has been available to treat this serious …